- CA-4948
-
- $0.00 / 100MG
-
2024-08-26
- CAS:1801343-74-7
- Min. Order: 1MG
- Purity: 98
- Supply Ability: 100G
|
| | CA-4948 Basic information |
| Product Name: | CA-4948 | | Synonyms: | CA-4948;CA 4948, CA-4948, CA4948;IRAK4-IN-7;CA 4948;CA4948;6'-Amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl][2,3'-bipyridine]-6-carboxamide;[2,3'-Bipyridine]-6-carboxamide, 6'-amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-;CA4948-Analog;IRAK4-IN-7 (CA4948 analog) | | CAS: | 1801343-74-7 | | MF: | C21H19N7O3 | | MW: | 417.42 | | EINECS: | | | Product Categories: | | | Mol File: | 1801343-74-7.mol |  |
| | CA-4948 Chemical Properties |
| Melting point | >294°C (dec.) | | density | 1.444±0.06 g/cm3(Predicted) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | 10.41±0.43(Predicted) | | form | Solid | | color | Pale Yellow to Brown | | InChI | InChI=1S/C21H19N7O3/c22-18-5-4-13(11-23-18)15-2-1-3-16(26-15)20(29)25-14-10-17-19(24-12-14)27-21(31-17)28-6-8-30-9-7-28/h1-5,10-12H,6-9H2,(H2,22,23)(H,25,29) | | InChIKey | RWIMETUXCNDSLE-UHFFFAOYSA-N | | SMILES | C1(C2=CC=C(N)N=C2)=NC(C(NC2=CN=C3N=C(N4CCOCC4)OC3=C2)=O)=CC=C1 |
| | CA-4948 Usage And Synthesis |
| Uses | 6''-Amino-N-[2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl][2,3''-bipyridine]-6-carboxamide was a useful reagent in preparation of bicyclic heterocyclyl derivatives as IRAK4 inhibitors. | | General Description | CA-4948 is a novel oral small-molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 is part of the Myddosome signaling pathway, and is essential for signaling downstream of toll-like receptors (TLR) and the interleukin-1 receptor (IL-1R) family in immune cells including B lymphocytes. . Dysregulated signaling in these pathways is frequently observed in Non-Hodgkin Lymphomas (NHL), particularly in ABC-subtype of Diffuse Large B-cell lymphoma (DLBCL) and Waldenstr?m macroglobulinemia (WM). Furthermore, IRAK4 activation has recently been identified as a driver of an adaptive resistance mechanism of malignancies. CA-4948 is the first clinical candidate targeting IRAK4 to be evaluated in cancer patients[1]. | | References | [1] G. Nowakowski. “Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study.” Blood 136 1 (2020): 44–45.
|
| | CA-4948 Preparation Products And Raw materials |
|